Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 7, 2019

Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months (P3.2-063)

Jerome De Seze, Gilles Edan, Thibault Moreau, Bruno Brochet, Frederic Sedel, Ayman Tourbah
First published April 16, 2019,
Jerome De Seze
1INSERM 1434, Department of Neurology and the Clinical Investigation Centre, CHU de Strasbourg, France Strasbourg France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Edan
2Service de Neurologie, CHU de Rennes, France Rennes France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thibault Moreau
3Department of Neurology, Dijon University Hospital, France Dijon France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Brochet
4Department of Neurology, CHU Pellegrin, University of Bordeaux, France Bordeaux France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic Sedel
5MedDay Pharmaceuticals, Paris, France Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayman Tourbah
6Department of Neurology, CHU de Reims, France Reims France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months (P3.2-063)
Jerome De Seze, Gilles Edan, Thibault Moreau, Bruno Brochet, Frederic Sedel, Ayman Tourbah
Neurology Apr 2019, 92 (15 Supplement) P3.2-063;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the effects of MD1003 during the open-label extension phase of the MS-SPI study.

Background: MS-SPI was a 12-month (M) double-blind study of MD1003 (n=103) vs placebo (n=51) in patients (pts) with nonactive progressive multiple sclerosis (PMS). As reported previously, expanded disability status scale (EDSS) and/or timed 25-foot walk improvement, mean EDSS (mEDSS) score, and clinical/subject global impression (CGI/SGI) score were all significantly (P<0.05) in favor of MD1003 vs placebo (Tourbah et al., 2016). In the open-label extension phase, all pts received MD1003. Here, we present data at 48M of follow-up (shown as MD1003>MD1003 [MM] vs placebo>MD1003 [PM]).

Design/Methods: A total of 133 pts (MM: 91; PM: 42) entered the extension phase. We assessed time to first decreased/increased EDSS (Kaplan-Meier), mEDSS change from baseline, and CGI/SGI.

Results: In time to first decreased/increased EDSS analyses up to 12M, the results favored MD1003 over placebo (hazard ratio [HR], 3.55 and 0.42, respectively), though they were not significant (P>0.05) in this relatively small study. In similar analyses up to 48M, the probability of improvement/worsening again favored MD1003 over placebo (HR, 2.47, P>0.05 and 0.80, P>0.05, respectively). Throughout the extension phase, the mean change in EDSS score was numerically lower in the MM group (vs PM group); the difference in mEDSS score between the MM and PM groups was significant at M18 (P<0.05) and M30 (P<0.05) but not at other timepoints. In the extension phase, CGI and SGI scores remained stable for MM pts and improved for PM pts upon switching to MD1003.

Conclusions: Results from the MS-SPI study at 4 years of follow-up indicate that 1) delayed MD1003 treatment results in higher disability over time, 2) pts show improvement when switching from placebo to MD1003, and 3) the effects of MD1003 observed in the double-blind phase are sustained over time.

Disclosure: Dr. De Seze has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi-Genzyme, Teva, Novartis, Roche, Chugai, and Alexion. Dr. De Seze has received research support from Sanofi. Dr. Edan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck, Novartis, Sanofi, Roche, LFB, Bayer AG. Dr. Edan has received research support from Novartis, Sanofi, Merck, Biogen, Roche and Teva. Dr. Moreau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Biogen, Merck, Roche, MedDay, Teva, and Sanofi-Genzyme. Dr. Moreau has received research support from Novartis, Biogen, Merck, Roche, MedDay, Teva, and Sanofi-Genzyme. Dr. Brochet has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Biogen, Genzyme, Medday. Dr. Brochet has received research support from Teva, Biogen, MedDay, Novartis, Roche, Actelion, Sanofi-Genzyme, Merck, Bayer. Dr. SEDEL has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with MedDay. Dr. SEDEL holds stock and/or stock options in MedDay stocks as part of employee’s compensation, which sponsored research in which Dr. SEDEL was involved as an investigator. Dr. Tourbah has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, MedDay, Merck Serono, Roche, Sanofi-Genzyme, Teva. Dr. Tourbah has received research support from Biogen, Novartis, MedDay, Merck Serono, Roche, Sanofi-Genzyme, Teva.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (3)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise